

CENTRAL PHARMACEUTICAL JOINT
STOCK COMPANY NO 2
NO: /

*(Issued according to the ministry of finance's
circular No. 200/2014/TT-BTC dated
December 22nd, 2014)*

FINANCIAL STATEMENTS

FOURTH QUARTER 2025

| | |
|----------------------------------|--------------|
| Balance Sheet | Form: B01-DN |
| Income Statement | Form: B02-DN |
| Cash Flow Statement | Form: B03-DN |
| Notes to the financial statement | Form: B09-DN |

Recipient:.....

Form B 01 - DN

BALANCE SHEET

Fourth Quarter

Unit: VND

| ASSETS | Codes | Notes | 31/12/2025 | 01/10/2025 |
|--|------------|-------------|------------------------|------------------------|
| A. CURRENT ASSETS | 100 | | 146.654.247.457 | 129.841.539.917 |
| I. Cash and cash equivalents | 110 | | 21.400.434.733 | 5.053.168.373 |
| 1. Cash | 111 | V.1. | 21.400.434.733 | 5.053.168.373 |
| II. Short-term financial investments | 120 | | - | - |
| III. Short-term receivables | 130 | | 83.103.532.608 | 76.690.595.733 |
| 1. Short-term trade accounts receivable | 131 | V.3. | 24.198.699.127 | 22.152.834.582 |
| 2. Advances to suppliers | 132 | V.4. | 6.401.339.091 | 913.567.035 |
| 3. Other short-term receivables | 136 | V.5. | 57.114.978.585 | 58.235.678.311 |
| 4. Allowances for short-term doubtful debts | 137 | V.6. | (4.611.484.195) | (4.611.484.195) |
| IV. Inventories | 140 | V.7. | 41.638.709.523 | 47.610.369.449 |
| 1. Inventories | 141 | | 41.638.709.523 | 47.610.369.449 |
| 2. Allowances for inventories | 149 | | - | - |
| V. Other short-term assets | 150 | | 511.570.593 | 487.406.362 |
| 1. Short-term prepayments | 151 | V.11. | 383.912.324 | 160.618.558 |
| 2. Deductible VAT | 152 | | 58.648.144 | 257.777.679 |
| 3. Taxes and other receivables from the State budget | 153 | V.14. | 69.010.125 | 69.010.125 |
| B. NON-CURRENT ASSETS | 200 | | 263.835.962.788 | 312.791.806.940 |
| I. Long-term receivables | 210 | | 45.000.000.000 | 72.240.000.000 |
| 1. Other long-term receivables | 216 | V.5. | 45.000.000.000 | 72.240.000.000 |
| II. Fixed assets | 220 | | 110.731.893.402 | 132.236.602.153 |
| 1. Tangible fixed assets | 221 | V.10. | 110.731.893.402 | 132.236.602.153 |
| - Historical cost | 222 | | 290.298.359.931 | 289.655.763.230 |
| - Accumulated depreciation | 223 | | (179.566.466.529) | (157.419.161.077) |
| 2. Intangible fixed assets | 227 | V.8. | - | - |
| - Historical cost | 228 | | 810.751.750 | 810.751.750 |
| - Accumulated amortization | 229 | | (810.751.750) | (810.751.750) |
| III. Investment property | 230 | | - | - |
| IV. Long-term assets in progress | 240 | | 30.725.661 | 76.805.661 |
| 1. Construction in progress | 242 | V.9. | 30.725.661 | 76.805.661 |
| V. Long-term financial investments | 250 | | 93.960.000.000 | 93.960.000.000 |
| 1. Equity investments in other entities | 253 | V.2. | 93.960.000.000 | 93.960.000.000 |
| VI. Other long-term assets | 260 | | 14.113.343.725 | 14.278.399.126 |
| 1. Long-term prepayments | 261 | V.11. | 14.113.343.725 | 14.278.399.126 |
| TOTAL ASSETS (270=100+200) | 270 | | 410.490.210.245 | 442.633.346.857 |



Unit: VND

| RESOURCES | Codes | Notes | 31/12/2025 | 01/10/2025 |
|--|------------|--------------|------------------------|------------------------|
| C LIABILITIES | 300 | | 339.827.970.257 | 361.660.487.896 |
| I. Current liabilities | 310 | | 245.867.970.257 | 267.700.487.896 |
| 1. Short-term trade accounts payable | 311 | V.12. | 17.299.573.532 | 19.658.618.096 |
| 2. Short-term advances from customers | 312 | V.13. | 25.438.207.912 | 18.990.940.376 |
| 3. Taxes and amounts payable to the State budget | 313 | V.14. | 54.060.186.509 | 54.006.314.179 |
| 4. Payables to employees | 314 | | 3.559.635.569 | 3.332.236.406 |
| 5. Short-term accrued expenses | 315 | V.15. | 46.655.322.489 | 38.669.880.463 |
| 6. Other short-term payables | 319 | V.17. | 1.354.412.160 | 30.861.866.290 |
| 7. Short-term loans and obligations under finance leases | 320 | V.16. | 97.215.578.312 | 101.895.578.312 |
| 8. Bonus and welfare funds | 322 | | 285.053.774 | 285.053.774 |
| II. Long-term liabilities | 330 | | 93.960.000.000 | 93.960.000.000 |
| 1. Other long-term payables | 337 | V.17. | 93.960.000.000 | 93.960.000.000 |
| 2. Long-term loans and obligations under finance leases | 338 | V.16. | - | - |
| D EQUITY | 400 | | 70.662.239.988 | 80.972.858.961 |
| I. Owner's equity | 410 | V.18. | 70.662.239.988 | 80.797.568.961 |
| 1. Owner's contributed capital | 411 | | 200.000.000.000 | 200.000.000.000 |
| - Ordinary shares carrying voting rights | 411a | | 200.000.000.000 | 200.000.000.000 |
| 2. Share premium | 412 | | 4.902.500.000 | 4.902.500.000 |
| 3. Investment and development fund | 418 | | 3.267.017.189 | 3.267.017.189 |
| 4. Other reserves | 420 | | 425.238.734 | 249.948.734 |
| 5. Retained earnings | 421 | | (137.932.515.935) | (127.621.896.962) |
| Retained earnings accumulated to the prior year end | 421a | | (127.621.896.962) | (122.067.787.967) |
| Retained earnings of current year | 421b | | (10.310.618.973) | (5.554.108.995) |
| II. Other resources and funds | 430 | | - | 175.290.000 |
| 1. Subsidised funds | 431 | | - | 175.290.000 |
| TOTAL RESOURCES (440=300+400) | 440 | | 410.490.210.245 | 442.633.346.857 |

Ha Noi, 14 January, 2026

CENTRAL PHARMACEUTICAL JOINT STOCK COMPANY NO2

Prepared by

Chief Accountant

General Director



Dinh Thi Minh Huong



Nguyen Thi Dieu Thuy



Le Tien Dung

CENTRAL PHARMACEUTICAL JOINT STOCK COMPANY NO2

FINANCIAL STATEMENTS

Address: No. 9 Tran Thanh Tong Street, Bach
Dang Ward, Hai Ba Trung District, Hanoi

Form B 02 - DN

INCOME STATEMENT

Fourth Quarter

Unit: VND

| | Items | Codes | Notes | Current quarter | Same quarter previous year | Cumulative figure from the beginning of current year to the end of current quarter | Cumulative figure from the beginning of the previous year to the end of the same quarter previous year |
|-----|--|-------|--------|-----------------|-------------------------------|---|--|
| 1. | Gross revenue from goods sold and services rendered | 01 | VI.1. | 44.994.085.239 | 51.750.058.130 | 200.471.437.158 | 200.432.039.681 |
| 2. | Deductions | 02 | VI.2. | - | - | 1.454.063.500 | 245.129.568 |
| 3. | Net revenue from goods sold and services rendered (10=01-02) | 10 | | 44.994.085.239 | 51.750.058.130 | 199.017.373.658 | 200.186.910.113 |
| 4. | Cost of sales | 11 | VI.3. | 40.840.324.466 | 47.132.785.658 | 174.182.756.838 | 182.437.005.741 |
| 5. | Gross profit from goods sold and services rendered (20=10-11) | 20 | | 4.153.760.773 | 4.617.272.472 | 24.834.616.820 | 17.749.904.372 |
| 6. | Financial income | 21 | VI.4. | 43.854.056 | 28.277.000 | 75.986.352 | 39.448.484 |
| 7. | Financial expenses | 22 | VI.5. | 3.714.059.776 | (4.095.627.839) | 13.166.598.463 | 5.235.494.574 |
| | In which: Interest expense | 23 | | 3.661.353.496 | (4.229.852.135) | 13.012.806.520 | 4.838.474.984 |
| 8. | Selling expenses | 25 | VI.8. | 842.888.252 | 1.507.570.669 | 3.480.354.248 | 3.943.260.744 |
| 9. | General and administration expenses | 26 | VI.8. | 3.727.667.670 | 3.845.746.561 | 14.389.267.156 | 13.534.655.637 |
| 10. | Operating profit {30=20+(21-22)-(24+25)} | 30 | | (4.087.000.869) | 2.212.451.265 | (6.405.056.978) | (6.106.059.881) |
| 11. | Other income | 31 | VI.6. | 108.859.115 | 436.286.375 | 263.927.280 | 1.819.418.874 |
| 12. | Other expenses | 32 | VI.7. | 935.780.595 | 623.547.009 | 4.169.489.275 | 1.267.467.988 |
| 13. | Profit from other activities (40=31-32) | 40 | | (826.921.480) | (187.260.634) | (3.905.561.995) | 551.950.886 |
| 14. | Accounting profit before tax (50=30+40) | 50 | | (4.913.922.349) | 2.025.190.631 | (10.310.618.973) | (5.554.108.995) |
| 15. | Current corporate income tax expense | 51 | VI.9. | - | - | - | - |
| 16. | Net profit after corporate income tax (60=50-51-52) | 60 | | (4.913.922.349) | 2.025.190.631 | (10.310.618.973) | (5.554.108.995) |
| 17. | Basic earning per share | 70 | VI.11. | - | - | - | - |

Ha Noi, 14 January, 2025

CENTRAL PHARMACEUTICAL JOINT STOCK COMPANY NO2


Prepared by

Chief Accountant

General Director



Dinh Thi Minh Huong



Nguyen Thi Dieu Thuy



Le Tien Dung

CENTRAL PHARMACEUTICAL JOINT STOCK COMPANY NO2 FINANCIAL STATEMENTS

Address: No. 9 Tran Thanh Tong Street, Bach
Dang Ward, Hai Ba Trung District, Hanoi

Form B 03 - DN

CASH FLOW STATEMENT

Fourth Quarter

Unit: VND

| Items | Codes | Notes | Cumulative figure from the beginning of current year to the end of current quarter | Cumulative figure from the beginning of the previous year to the end of the same quarter previous year |
|--|-----------|-------|---|---|
| I. Cash flow from operating activities | | | | |
| 1. Revenue from sales and services and other income | 01 | | 57.011.443.519 | 52.738.507.874 |
| 2. Payments to suppliers of goods and services | 02 | | (42.580.618.448) | (45.314.319.471) |
| 3. Cash paid to employees | 03 | | (5.257.878.805) | (5.419.405.215) |
| 4. Paid loan interest | 04 | | (136.670.000) | (1.706.255.300) |
| 5. Paid corporate income tax | 05 | | - | - |
| 6. Other cash inflows from operating activities | 06 | | 6.456.849.801 | 5.179.489.843 |
| 7. Other cash outflows from operating activities | 07 | | (7.786.126.419) | (11.534.909.011) |
| Net cash flow used in operating | 20 | | 7.706.999.648 | (6.056.891.280) |
| II. Cash flow from investing activities | | | | |
| 1. Acquisition and construction of fixed assets and other non-current assets | 21 | | - | - |
| 2. Interest earned, dividends and received profits | 27 | | - | - |
| Net cash flow used in investing | 30 | | - | - |
| III. Cash flow from financing activities | | | | |
| 1. Proceeds from borrowing | 33 | | - | - |
| 2. Prepayment of borrowing | 34 | | (4.100.000.000) | (2.515.000.000) |



| | | | |
|--|----|--------------------|-----------------|
| 3. Dividends and profits paid to owners | 36 | - | - |
| <i>Net cash flow from financing activities</i> | 40 | (4.100.000.000) | (2.515.000.000) |
| Net increase/decrease in cash (50 = 20+30+40) | 50 | 3.606.999.648 | (8.571.891.280) |
| Cash and cash equivalents at the beginning of the year | 60 | 17.793.435.085 | 13.625.059.653 |
| Effect of changes in foreign exchange rates | 61 | - | - |
| Cash and cash equivalents at the end of the year (70 = 50+60+61) | 70 | V.1 21.400.434.733 | 5.053.168.373 |

Hà Nội, 14 January, 2025

CENTRAL PHARMACEUTICAL JOINT STOCK COMPANY NO2

Prepared by

Chief Accountant

General Director



Dinh Thi Minh Huong



Nguyen Thi Dieu Thuy



Le Tien Dung

(The notes from page 10 to page 32 are an integral part of these Financial Statements)



NOTES TO THE FINANCIAL STATEMENTS

(These notes are an integral part of and should be read in conjunction with the accompanying Financial Statements.)

I. Additional information for items presented in the Balance Sheet

| 1. Cash | 31/12/2025 | 01/01/2025 |
|--------------|-----------------------|----------------------|
| | VND | VND |
| Cash on hand | 335.663.349 | 594.457.069 |
| Cash in bank | 21.064.771.384 | 4.458.711.304 |
| Total | 21.400.434.733 | 5.053.168.373 |

2. Financial investments

Investments in other entities

| | 31/12/2025 | | 01/01/2025 | |
|--|-----------------------|-----------|-----------------------|-----------|
| | VND | | VND | |
| | Historical cost | Provision | Historical cost | Provision |
| <i>Long-term</i> | | | | |
| Binh An Developed Investment Joint Stock Company (i) | 93.960.000.000 | - | 93.960.000.000 | - |
| Total | 93.960.000.000 | - | 93.960.000.000 | - |

3. Trade receivables

| | 31/12/2025 | | 01/01/2025 | |
|---------------------------------|-----------------------|-----------|-----------------------|-----------|
| | VND | | VND | |
| | Amount | Provision | Amount | Provision |
| <i>Short-term</i> | | | | |
| Central Pharmaceutical CPC1.JSC | - | - | - | - |
| Vinh Quang Independent | 765.776.634 | - | 1.179.863.634 | - |
| Tam Phat Pharmaceutical | 3.818.870.208 | - | 2.431.803.708 | - |
| Huong Viet Pharmaceutical JSC | 1.358.617.919 | - | 2.361.553.219 | - |
| Sapphire Pharmaceutical | 1.048.414.352 | - | 1.048.414.352 | - |
| Others | 17.205.036.134 | - | 15.131.199.669 | - |
| Total | 24.196.715.247 | - | 22.152.834.582 | - |

4. Advances to suppliers

| | 31/12/2025 | 01/01/2025 |
|---|---------------|------------|
| | VND | VND |
| BMN Medical and Scientific Instrument Company | 2.064.461.000 | - |
| VIET NAM Auditing & Evaluation Company Ltd | - | 35.000.000 |
| MEDIPLANTEX „JSC | 2.622.231.197 | - |

NOTES TO THE FINANCIAL STATEMENTS

(These notes are an integral part of and should be read in conjunction with the accompanying Financial Statements.)

| | | |
|--------------|----------------------|--------------------|
| Others | 1.668.566.894 | 878.567.035 |
| Total | 6.355.259.091 | 913.567.035 |

5. Other receivables

| | 31/12/2025 | | 01/01/2025 | |
|--|-----------------------|-----------|------------------------|-----------|
| | VND | | VND | |
| | Amount | Provision | Amount | Provision |
| a) Short-term | 57.114.978.585 | | 58.235.678.311 | |
| Advances | 133.627.426 | | 166.917.426 | |
| <i>Vu Thi Thu Hang</i> | <i>41.302.000</i> | | <i>41.302.000</i> | |
| <i>Others</i> | <i>92.325.426</i> | | <i>125.615.426</i> | |
| Mortgages, collaterals | 468.895.076 | | 937.656.060 | |
| Social insurance paid for: | 1.081.477.763 | | 1.953.222.422 | |
| Other receivables | 55.430.978.320 | | 55.177.882.403 | |
| <i>Binh An Developed Investment JSC (i)</i> | <i>49.600.314.938</i> | | <i>49.600.314.938</i> | |
| <i>Tran Bao Cuong</i> | <i>2.320.000.000</i> | | <i>2.320.000.000</i> | |
| <i>Others</i> | <i>3.510.663.382</i> | | <i>3.257.567.465</i> | |
| b) Long-term | - | - | 72.240.000.000 | - |
| Other receivables | - | - | 72.240.000.000 | - |
| <i>Nhat Minh Production Company Limited (ii)</i> | | - | <i>72.240.000.000</i> | <i>-</i> |
| Total | 57.114.978.585 | - | 130.475.678.311 | - |

6 Inventories

| | 31/12/2025 | | 01/01/2025 | |
|--------------------|-----------------------|-----------|-----------------------|-----------|
| | VND | | VND | |
| | Cost | Provision | Cost | Provision |
| Raw material | 29.311.927.146 | - | 27.393.596.296 | - |
| Tools and supplies | 62.419.342 | - | 9.118.366 | - |
| Work in progress | 1.769.200.351 | - | 6.376.772.136 | - |
| Finished goods | 10.495.162.684 | - | 13.830.882.651 | - |
| Total | 41.638.709.523 | - | 47.610.369.449 | - |

7. Construction in progress

| | 31/12/2025 | 01/01/2025 |
|--|------------|------------|
| | VND | VND |

NOTES TO THE FINANCIAL STATEMENTS

(These notes are an integral part of and should be read in conjunction with the accompanying Financial Statements.)

| | | |
|---------------------------------|-------------------|-------------------|
| Cao Xoa production line project | - | - |
| Vinh Tuy complex building | 76.805.661 | 76.805.661 |
| Total | 76.805.661 | 76.805.661 |

8. Trade payables

| | 31/12/2025 | | 01/01/2025 | |
|--|-----------------------|-----------------------|-----------------------|-----------------------|
| | VND | | VND | |
| | Historical cost | Amount payable | Historical cost | Amount payable |
| <i>Short-term</i> | | | | |
| VCP.,JSC | - | - | - | - |
| Van Son International Economic and Technical Cooperation | 7.346.050.277 | 7.346.050.277 | 7.346.050.277 | 7.346.050.277 |
| MI Pharma Private Limited | 1.630.205.570 | 1.630.205.570 | 2.159.462.950 | 2.159.462.950 |
| Aristopharma LTD | - | - | - | - |
| Others | 8.323.317.685 | 8.323.317.685 | 10.153.104.869 | 10.153.104.869 |
| Total | 17.299.573.532 | 17.299.573.532 | 19.658.618.096 | 19.658.618.096 |

9. Advances from customers

| | 31/12/2025 | 01/01/2025 |
|---|-----------------------|-----------------------|
| | VND | VND |
| <i>Short-term</i> | | |
| Generic Phamaceutical JSC | - | 973.530.932 |
| South East Of Asia Pharma.,JSC | 4.111.326.121 | 1.518.956.641 |
| Southeast Asia Pharmaceutical and Medical Equipment JSC | - | - |
| Xuan Anh Pharmaceutical and Equipment Company Limited | 12.638.838.283 | 6.966.231.329 |
| SINH PHUC PTT CO. LTD | - | - |
| Capital Pharmacy.,JSC | - | 1.374.059.046 |
| HA MINH TECHNO CO., LTD | - | - |
| HUNG VIET TRADING AND PHARMACEUTICAL JOINT STOCK CO | 721.146.389 | 1.205.443.823 |
| Others | 7.964.913.239 | 6.952.718.605 |
| Total | 25.436.224.032 | 18.990.940.376 |

10. Other payables

| 31/12/2025 | 01/01/2025 |
|------------|------------|
| VND | VND |

NOTES TO THE FINANCIAL STATEMENTS

(These notes are an integral part of and should be read in conjunction with the accompanying Financial Statements.)

| | | |
|--|-----------------------|------------------------|
| a) Short-term | 1.354.412.160 | 30.861.866.290 |
| Trade Union Fee | 828.723.051 | 1.345.941.665 |
| Other payables | 525.689.109 | 29.515.924.625 |
| Nhat Minh Production Company Limited Branch in Hanoi (i) | - | 26.410.000.000 |
| Others | 525.689.109 | 3.105.924.625 |
| b) Long-term | 93.960.000.000 | 93.960.000.000 |
| Other payables | 93.960.000.000 | 93.960.000.000 |
| Binh An Developed Investment Joint Stock Company (ii) | 93.960.000.000 | 93.960.000.000 |
| Total | 95.314.412.160 | 124.821.866.290 |

11. Owner's equity

Details of owner's equity contribution

| | 31/12/2025 | 01/01/2025 |
|---|------------------------|------------------------|
| | VND | VND |
| Vietnam Pharmaceutical Corporation - JSC | 13.566.500.000 | 13.566.500.000 |
| Viet Land Corporation | 24.748.000.000 | 24.748.000.000 |
| Saigon Handicraft Fine Art Export Joint Stock Company | 150.000.000.000 | 150.000.000.000 |
| Other shareholders | 11.685.500.000 | 11.685.500.000 |
| Total | 200.000.000.000 | 200.000.000.000 |

II. Additional information for items presented in the Income Statement

1. Gross revenue from goods sold and services rendered

| | Q4/2025 | Q4/2024 |
|---|-----------------------|-----------------------|
| | VND | VND |
| Revenue | | |
| Revenue from sales of goods | - | - |
| Revenue from sales of finished products | 44.994.085.239 | 51.750.058.130 |
| Total | 44.994.085.239 | 51.750.058.130 |

2. Revenue deductions

| | Q4/2025 | Q4/2024 |
|---------------|----------|--------------------|
| | VND | VND |
| Sales Returns | - | - |
| Total | - | 198.498.472 |

3. Cost of sales

NOTES TO THE FINANCIAL STATEMENTS*(These notes are an integral part of and should be read in conjunction with the accompanying Financial Statements.)*

| | Q4/2025 VND | Q4/2024 VND |
|---|-----------------------|------------------------|
| Cost of goods sold | - | - |
| Cost of finished goods sold | 40.840.324.466 | 47.132.785.658 |
| Total | 40.840.324.466 | 47.132.785.658 |
| 4. Financial income | | |
| | Q4/2025 VND | Q4/2024 VND |
| Interest on bank deposits and margin interest | 9.229.406 | 6.733.600 |
| Exchange rate difference interest arises during the year | 34.624.650 | 21.543.400 |
| Gain from exchange rate difference due to revaluation at the year end | - | - |
| Total | 43.854.056 | 28.277.000 |
| 5. Financial expenses | | |
| | Q4/2025 VND | Q4/2024 VND |
| Interest expense | 3.661.353.496 | (4.229.852.135) |
| Interest on late payment | - | - |
| Exchange rate difference loss arising during the year | 52.706.280 | 134.224.296 |
| Loss from exchange rate difference due to revaluation at the year end | - | - |
| Total | 3.714.059.776 | (4.095.627.839) |
| 6. Other income | | |
| | Q4/2025 VND | Q4/2024 VND |
| Income from warehouse leasing | 103.957.953 | 376.002.000 |
| Income from liabilities that are not payable | - | - |
| Other | 4.901.162 | 60.264.575 |
| Total | 108.859.115 | 436.266.575 |
| 7. Other expenses | | |
| | Q4/2025 VND | Q4/2024 VND |
| Administrative fines and late payment of taxes and insurance | - | - |
| Liquidation of defective raw materials and finished goods | - | - |
| Excess materials used for waste disposal | - | - |

NOTES TO THE FINANCIAL STATEMENTS

(These notes are an integral part of and should be read in conjunction with the accompanying Financial Statements.)

| | | |
|-------|--------------------|--------------------|
| Other | 935.780.595 | 623.547.009 |
| Total | <u>935.780.595</u> | <u>623.547.009</u> |

Ha Noi, 14 January, 2025

CENTRAL PHARMACEUTICAL JOINT STOCK COMPANY NO2

Prepared by

Chief Accountant

General Director



Dinh Thi Minh Huong



Nguyen Thi Dieu Thuy



Le Tien Dung

CENTRAL PHARMACEUTICAL
JOINT STOCK COMPANY NO2SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

No.: 16 /CBTT-DPTU2

Hanoi, January 14, 2026

PERIODIC DISCLOSURE OF FINANCIAL STATEMENTS

To: Hanoi Stock Exchange

4nd quarter 2025 with Hanoi Stock Exchange as follows:

Pursuant to the provisions of Clause 3, Article 14 of Circular No. 96/2020/TT-BTC dated November 16, 2020 of the Ministry of Finance guiding disclosures on the stock market, Central Pharmaceutical Joint Stock Company No2 shall disclose information on the financial statements (FS) 4nd quarter 2025 with Hanoi Stock Exchange as follows:

1. Company name:

- Ticker symbol: DP2
- Address: No. 9 Tran Thanh Tong Street, Ward Hai Ba Trung District, Hanoi.
- Tel: 024 39716579/91: Fax: 024 35251484.
- Email: dopharma@dopharma.com.vn.
- Website: wwwdophrma.com.vn _ dopharma.vn

2. Disclosures:

- Financial statements for the 4st quarterof 2025

☒ Separate financial statements (The listed company has no subsidiaries and the superior accounting entity has affiliates);

☐ Consolidated financial statements (the listed company has subsidiaries);

☐ Combined financial statements (the listed company has affiliated accounting entities with separate accounting apparatus).

- Cases that require explanation:

+ The auditors gave an opinion that was not an unqualified opinion on the financial statements (for audited financial statements in 2024):

☒ Yes

☐ No

Explanatory document where you mark the box "Yes":

☒ Yes

☐ No

+ The difference between pre- and post-audit profit in the reporting period is 5% or more, transferring from loss to profit or vice versa (for audited financial statements in 2024):



☐ Yes

☐ No

Explanatory document where you mark the box "Yes":

☐ Yes

☐ No

+ Profit after corporate income tax in the income statement of the reporting period changes by 10% or more compared to the same reporting period of the previous year:

☒ Yes

☐ No

Explanatory document where you mark the box "Yes":

☒ Yes

☐ No

+ Profit after tax in the reporting period is a loss, transferring from profit in the same period of the previous year to loss in this period or vice versa:

☐ Yes

☐ No

Explanatory document where you mark the box "Yes":

☐ Yes

☐ No

This information was announced on the company's website on January 20, 2026 at the link: www.dopharma.com.vn _ dopharma.vn

Attachments:

- Financial report for the fourth quarter of 2025
- Document explaining the financial statements for the fourth quarter of 2025

For the Company
Legal representative/ person authorized to make disclosures
(Signature, full name, position, seal)



Pharmacist Le Tien Dung

